Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 27.16M 19.47M 17.43M 16.04M 14.53M 1.85B 27.67M 191M 76.77M 972M 73.06M 71.5M 3.07B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 26.93M 19.3M 17.29M 15.9M 14.41M 1.83B 27.43M 190M 76.12M 964M 72.44M 70.9M 3.04B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
1 week-7.69%
1 month-7.69%
3 months-7.69%
6 months+9.09%
Current year-29.41%
1 week 0.12
Extreme 0.115
0.14
1 month 0.12
Extreme 0.115
0.14
Current year 0.07
Extreme 0.07
0.19
1 year 0.07
Extreme 0.07
0.2
3 years 0.04
Extreme 0.035
0.36
5 years 0.04
Extreme 0.035
0.36
10 years 0.04
Extreme 0.035
0.36
Manager TitleAgeSince
Chief Executive Officer - 01/07/2019
Director of Finance/CFO - 17/08/2022
Chief Tech/Sci/R&D Officer - 17/09/2024
Director TitleAgeSince
Director/Board Member - 06/12/2017
Director/Board Member - 01/07/2019
Chairman - 30/04/2025
Date Insider Type Main position Quantity % Market Cap. Importance
16/3/26 Option 16,367 0.0092% -
16/3/26 Other 0 0% -
9/3/26 Option

Executive/Senior Manager

150,000 0.0840%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-7.69%-25.00%+166.67% 19.47M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.88%+4.54%+39.42%+92.77% 426.19B
Weighted average by Cap. +2.01%+6.60%+50.51%+100.44%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.42 0.03 0.03 1.32
Net income -1.71M -1.22M -1.1M -1.01M -913K -116M -1.74M -12.02M -4.83M -61.11M -4.59M -4.49M -193M -3.53M -2.53M -2.27M -2.09M -1.89M -240M -3.6M -24.87M -9.98M -126M -9.5M -9.3M -399M
Net Debt -113K -80.72K -72.3K -66.5K -60.26K -7.66M -115K -793K -318K -4.03M -303K -297K -12.72M -231K -165K -148K -136K -123K -15.69M -235K -1.62M -652K -8.25M -620K -607K -26.03M
Projected Income Statement - Annual - Voyageur Pharmaceuticals Ltd.
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-
Date Price Change Volume
30/10/26 CAD 0.1200 -.--% 21,501
29/10/26 CAD 0.1200 -.--% 108,580
28/10/26 CAD 0.1200 -14.29% 148,500
27/10/26 CAD 0.1400 +16.67% 175,500
26/10/26 CAD 0.1200 -7.69% 120,700

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Voyageur Pharmaceuticals Ltd.